Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease

Journal of the American Society of Nephrology

Volumn 20, Issue 9, 2009, Pages 1888-1893

  Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL EXPANSION; CELL PROLIFERATION; CIRCULATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; KIDNEY CYST; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY POLYCYSTIC DISEASE; KIDNEY VASCULAR RESISTANCE; MONOTHERAPY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SYMPATHETIC TONE; TREATMENT RESPONSE; URINE VOLUME;

HUMANS; HYPERTENSION, RENAL; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM;

EID: 69849098859     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008080882     Document Type: Short Survey

References (40)

1. Pretorius DH, Lee ME, Manco-Johnson ML, Weingast GR, Sedman AB, Gabow PA: Diagnosis of autosomal dominant polycystic kidney disease in utero and in the young infant. J Ultrasound Med 6: 249-255, 1987 (Pubitemid 17075032)
2. MacDermot KD, Saggar-Malik AK, Economides DL, Jeffery S: Prenatal diagnosis of autosomal dominant polycystic kidney disease (PKD1) presenting in utero and prognosis for very early onset disease. J Med Genet 35: 13-16, 1998
3. Shamshirsaz A, Bekheirnia MR, Kamgar M, Johnson AM, McFann K, Cadapaphornchai M, Nobakht N, Schrier RW: Autosomal dominant polycystic kidney disease I infancy and childhood: Progression and outcome. Kidney Int 68: 2218-2224, 2005 (Pubitemid 43117796)
4. Cadnapaphonchai M, McFann K, Strain JD, Masoumi A, Schrier RW: Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74: 1192-1196, 2008
5. Cadnapaphonchai M, McFann M, Strain J, Masoumi A, Schrier RW: Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4: 820-829, 2009
6. Ecder T, Fick-Brosnahan G, Schrier RW: Polycystic kidney disease. In: Diseases of the Kidney and Urinary Tract, 8th Ed., edited by Schrier RW, Philadelphia, Lippincott Williams & Wilkins, 2006, pp 502-539
7. Ettinger A, Kahn PC, Wise HM Jr: The importance of selective renal angiography in the diagnosis of polycystic disease. J Urol 102: 156-161, 1969
8. Eckardt KU, Möllmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U: Erythropoietin in polycystic kidneys. J Clin Invest 84: 1160-1166, 1989
9. Valvo E, Gammaro L, Tessitore N, Panzetta G, Lupo A, Loschiavo C, Oldrizzi L, Fabris A, Rugiu C, Ortalda V, et al.: Hypertension of polycystic kidney disease: Mechanisms and hemodynamic alterations. Am J Nephrol 5: 176-181, 1985 (Pubitemid 15120351)
10. Anderson RJ, Miller PD, Linas SL, Katz FH, Holmes JH: Role of the renin-angiotensin system in hypertension of polycystic kidney disease. Miner Electrolyte Metab 2: 137-141, 1979 (Pubitemid 9198697)
11. Bell PE, Hossack KF, Gabow PA, Durr JA, Manco-Johnson M, Schrier RW: Hypertension in autosomal dominant polycystic kidney disease: Potential role of increased cardiac index and impaired renal response. Kidney Int 34: 683-694, 1988
12. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin- aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323: 1091-1096, 1990 (Pubitemid 20370729)
13. Graham PC, Lindop GB: The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 33: 1084-1090, 1988 (Pubitemid 18151896)
14. Loghman-Adham M, Soto CE, Inagami T, Cassis L: The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 287: F775-F788, 2004 (Pubitemid 39280514)
15. Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW: Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38: 1177-1180, 1990
16. Fick-Brosnahan G, Belz M, McFann K, Johnson A, Schrier RW: Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study. Am J Kidney Dis 39: 1127-1134, 2002 (Pubitemid 34591926)
17. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 35: 427-432, 2000
18. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 1349-1354, 1994 (Pubitemid 24977120)
19. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8: 1292-1297, 1997 (Pubitemid 27493634)
20. Fick GM, Johnson AM, Hammond WS, Gabow P: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 2048-2056, 1995
21. Levin A, Singer J, Thompson C, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27: 347-354, 1996 (Pubitemid 26075843)
22. Ceresola G, Vecchi M, Mulé G, Cottone S, Mangano MT, Andronico G, Contorno A, Parrino I, Renda F, Pavone G: Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am J Nephrol 18: 391-398, 1998 (Pubitemid 28442101)
23. Hocher B, Zart R, Schwarz A, Vogt V, Braun C, Thöne-Reineke C, Braun N, Neumayer HH, Koppenhagen K, Bauer C, Rohmeiss P: Renal endothelin system in polycystic kidney disease. J Am Soc Nephrol 9: 1169-1177, 1998 (Pubitemid 28283879)
24. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, Cheng TH: Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 61: 159-168, 2004 (Pubitemid 38056692)
25. Namli S, Oflaz H, Turgut F, Alisir S, Tufan F, Ucar A, Mercanoglu F, Ecder T: Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren Fail 29: 55-59, 2007 (Pubitemid 46254514)
26. Agarwal R, Campbell RC, Warnock DG: Oxidative stress in hypertension and chronic kidney disease: Role of angiotensin II. Semin Nephrol 24: 101-114, 2004 (Pubitemid 38387851)
27. Schrier RW, Shamshirsaz A: Autosomal dominant polycystic kidney disease: The renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy. Curr Med Lit - Nephrol and Hypertension, 10: 49-55, 2004
28. Ecder T, Schrier RW: Hypertension in autosomal dominant polycystic kidney disease: Early occurrence and unique aspects. J Am Soc Nephrol 12: 194-200, 2001 (Pubitemid 32056806)
29. Harrap SB, Davies DL, Macnicol AM, Dominiczak AF, Fraser R, Wright AF, Watson ML, Briggs JD: Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 40: 501-508, 1991
30. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 52: 1497-1510, 1997
31. Lumiaho A, Pihlajamäki J, Hartikainen J, Ikäheimo R, Miettinen R, Niemitukia L, Lampainen E, Laakso M: Insulin resistance is related to left ventricular hypertrophy in patients with polycystic kidney disease type 1. Am J Kidney Dis 41: 1219-1224, 2003 (Pubitemid 36637977)
32. Valero FA, Martinez-Vea A, Bardaji A, Gutierrez C, Garcia C, Richart C, Oliver JA: Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10: 1020-1026, 1999 (Pubitemid 29203089)
33. Ecder T, Edelstein CL, Chapman AB, Johnson Am, Tison L, Gill EA, Brosnahan GM, Schrier RW: Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 4-5: 1113-1116, 1999 (Pubitemid 29209293)
34. Schrier RW, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 13: 1733-1739, 2002 (Pubitemid 34700597)
35. Ecder T, Edelstein CL, Fick-Brosnahan G, Johnson AM, Chapman AB, Gabow PA, Schrier RW: Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21: 98-103, 2001 (Pubitemid 32453687)
36. Schrier RW, McFann K, Johnson A: Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 63: 678-685, 2003 (Pubitemid 36126815)
37. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996
38. Watson ML, Macnicol AM, Allan PL, Wright AF: Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 41: 206-210, 1992
39. McPherson EA, Luo Z, Brown RA, LeBard LS, Corless CC, Speth RC, Bagby SP: Chymase-like angiotensin II-generating activity in endstage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol 25: 493-5000, 2004 (Pubitemid 38140792)
40. Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett, Meyers CM, Thompson PA, Miller JP: Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: The Consortium for Radiologic Imagining Studies of Polycystic Kidney Disease Cohort. J Am Soc Nephrol 17: 854-862, 2006